{"id":2010,"date":"2024-04-10T14:20:48","date_gmt":"2024-04-10T14:20:48","guid":{"rendered":"https:\/\/stoxpo.com\/?p=2010"},"modified":"2024-04-10T14:20:49","modified_gmt":"2024-04-10T14:20:49","slug":"advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/","title":{"rendered":"Advancing Addiction Treatment: Adial Pharmaceuticals&#8217; AD04 Shows Promise in Clinical Study"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Adial Pharmaceuticals (ADIL), a pioneer in addiction treatment, celebrates a significant milestone with the publication of a peer-reviewed article showcasing the promising results of its lead investigational drug, AD04, in combating Alcohol Use Disorder (AUD). The study, published in the European Journal of Internal Medicine, underscores the robust safety profile and high compliance observed among patients administered AD04.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The comprehensive analysis of AD04&#8217;s liver safety profile compared to a placebo offers encouraging insights for individuals battling AUD, a condition associated with severe health risks and alcohol-associated liver disease (ALD). Notably, AD04 demonstrated no significant adverse effects and maintained liver biochemical parameters, indicating its potential as a precision treatment option.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cary Claiborne, CEO of Adial, lauds the publication as a pivotal step towards addressing the critical needs of individuals suffering from AUD and ALD. With AD04&#8217;s outstanding safety profile and therapeutic potential, Adial Pharmaceuticals aims to revolutionize addiction treatment and improve the lives of millions worldwide.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read original press release:<mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\"> <a href=\"https:\/\/finance.yahoo.com\/news\/adial-pharmaceuticals-announces-peer-reviewed-123000901.html\">here<\/a><\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\"> <a href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/the-bitcoin-halving-insights-from-ceos-and-its-impact-on-mining-companies\/\">The Bitcoin Halving: Insights from CEOs and its Impact on Mining Companies<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder Adial Pharmaceuticals (ADIL), a pioneer in addiction treatment, celebrates a significant milestone with the publication of a peer-reviewed article showcasing the promising results of its lead investigational drug, AD04, in combating Alcohol Use Disorder (AUD). The study, published in the European [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"1","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"1","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[358,309],"tags":[],"coauthors":[453],"class_list":["post-2010","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-micro-cap","category-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advancing Addiction Treatment: Adial Pharmaceuticals&#039; AD04 Shows Promise in Clinical Study - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancing Addiction Treatment: Adial Pharmaceuticals&#039; AD04 Shows Promise in Clinical Study - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder Adial Pharmaceuticals (ADIL), a pioneer in addiction treatment, celebrates a significant milestone with the publication of a peer-reviewed article showcasing the promising results of its lead investigational drug, AD04, in combating Alcohol Use Disorder (AUD). The study, published in the European [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-10T14:20:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-10T14:20:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Advancing Addiction Treatment: Adial Pharmaceuticals&#8217; AD04 Shows Promise in Clinical Study\",\"datePublished\":\"2024-04-10T14:20:48+00:00\",\"dateModified\":\"2024-04-10T14:20:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/\"},\"wordCount\":204,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"articleSection\":[\"Micro-Cap\",\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/\",\"name\":\"Advancing Addiction Treatment: Adial Pharmaceuticals' AD04 Shows Promise in Clinical Study - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"datePublished\":\"2024-04-10T14:20:48+00:00\",\"dateModified\":\"2024-04-10T14:20:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"width\":2560,\"height\":1709,\"caption\":\"chemistry-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2024\\\/04\\\/10\\\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advancing Addiction Treatment: Adial Pharmaceuticals&#8217; AD04 Shows Promise in Clinical Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advancing Addiction Treatment: Adial Pharmaceuticals' AD04 Shows Promise in Clinical Study - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/","og_locale":"en_US","og_type":"article","og_title":"Advancing Addiction Treatment: Adial Pharmaceuticals' AD04 Shows Promise in Clinical Study - Stoxpo","og_description":"Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder Adial Pharmaceuticals (ADIL), a pioneer in addiction treatment, celebrates a significant milestone with the publication of a peer-reviewed article showcasing the promising results of its lead investigational drug, AD04, in combating Alcohol Use Disorder (AUD). The study, published in the European [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/","og_site_name":"Stoxpo","article_published_time":"2024-04-10T14:20:48+00:00","article_modified_time":"2024-04-10T14:20:49+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Advancing Addiction Treatment: Adial Pharmaceuticals&#8217; AD04 Shows Promise in Clinical Study","datePublished":"2024-04-10T14:20:48+00:00","dateModified":"2024-04-10T14:20:49+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/"},"wordCount":204,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","articleSection":["Micro-Cap","Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/","url":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/","name":"Advancing Addiction Treatment: Adial Pharmaceuticals' AD04 Shows Promise in Clinical Study - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","datePublished":"2024-04-10T14:20:48+00:00","dateModified":"2024-04-10T14:20:49+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","width":2560,"height":1709,"caption":"chemistry-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2024\/04\/10\/advancing-addiction-treatment-adial-pharmaceuticals-ad04-shows-promise-in-clinical-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Advancing Addiction Treatment: Adial Pharmaceuticals&#8217; AD04 Shows Promise in Clinical Study"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=2010"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2010\/revisions"}],"predecessor-version":[{"id":2011,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/2010\/revisions\/2011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1429"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=2010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=2010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=2010"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=2010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}